A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy: Recent Episodes
Annenberg Center for Health Sciences
In this activity, Jeremy Abramson, MD, highlights the significant disease burden of B-cell lymphomas, as well as the latest advances in therapeutics, and practical strategies for integrating novel therapies into practice through patient selection and supportive care management.
Large B-cell lymphomas (LBCLs) are one of the most common subtypes of non-Hodgkin lymphomas and while 1st-line standard of care has remained unchanged, the treatment paradigm has undergone a shift in recent years due to the development of novel therapeutic agents. These novel therapies include monoclonal antibody (mAb) therapies, mAb-conjugates, and chimeric antigen receptor (CAR)-T cell therapies.
B-cell lymphomas consist of a heterogenous group of lymphoproliferative neoplasms originating from B-lymphocytes.
Management of relapsed/refractory LBCLs remains a substantial and persistent clinical challenge, including optimal treatment sequencing, therapy evaluation and patient selection, and toxicity management.